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Abstract
Background To investigate the predictive value of clinical and
biological markers for a pathological complete remission after a
preoperative dose-dense regimen of doxorubicin and docetaxel,
with or without tamoxifen, in primary operable breast cancer.
Methods Patients with a histologically confirmed diagnosis of
previously untreated, operable, and measurable primary breast
cancer (tumour (T), nodes (N) and metastases (M) score: T2-3(≥
3 cm) N0-2 M0) were treated in a prospectively randomised trial
with four cycles of dose-dense (bi-weekly) doxorubicin and
docetaxel (ddAT) chemotherapy, with or without tamoxifen, prior
to surgery. Clinical and pathological parameters (menopausal
status, clinical tumour size and nodal status, grade, and clinical
response after two cycles) and a panel of biomarkers (oestrogen
and progesterone receptors, Ki-67, human epidermal growth
factor receptor 2 (HER2), p53, bcl-2, all detected by
immunohistochemistry) were correlated with the detection of a
pathological complete response (pCR).
Results A pCR was observed in 9.7% in 248 patients
randomised in the study and in 8.6% in the subset of 196
patients with available tumour tissue. Clinically negative axillary
lymph nodes, poor tumour differentiation, negative oestrogen
receptor status, negative progesterone receptor status, and loss
of bcl-2 were significantly predictive for a pCR in a univariate
logistic regression model, whereas in a multivariate analysis only
the clinical nodal status and hormonal receptor status provided
significantly independent information. Backward stepwise
logistic regression revealed a response after two cycles, with
hormone receptor status and lymph-node status as significant
predictors. Patients with a low percentage of cells stained
positive for Ki-67 showed a better response when treated with
tamoxifen, whereas patients with a high percentage of Ki-67
positive cells did not have an additional benefit when treated
with tamoxifen. Tumours overexpressing HER2 showed a similar
response to that in HER2-negative patients when treated
without tamoxifen, but when HER2-positive tumours were
treated with tamoxifen, no pCR was observed.
Conclusion Reliable prediction of a pathological complete
response after preoperative chemotherapy is not possible with
clinical and biological factors routinely determined before start
of treatment. The response after two cycles of chemotherapy is
a strong but dependent predictor. The only independent factor
in this subset of patients was bcl-2.
Trial registration number NCT00543829
cCR = clinical complete response; CI = confidence interval; cNC = clinical no change; cPD = clinical progressive disease; cPR = clinical partial
response; ddAT = dose-dense Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER = oestrogen receptor; MRI = magnetic resonance imaging;Page 1 of 11
(page number not for citation purposes)
pCR = pathological complete remission; PgR = progesterone receptor.
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Preoperative (neo-adjuvant) chemotherapy in primary operable
breast cancer has been shown to produce an outcome equiv-
alent to that of postoperative (adjuvant) chemotherapy [1,2]. In
case of neo-adjuvant therapy, patients with a complete remis-
sion of the primary tumour have a better prognosis than
patients with a partial remission, or those with stable or pro-
gressive disease [3]. This has led to the hypothesis that the
response of the primary tumour in the breast parallels the
response of distant micrometastases, and that it can therefore
be used as a surrogate parameter for clinical outcome. Ran-
domised preoperative trials have, in contrast to trials in meta-
static disease, the advantage of offering a relatively
homogeneous population of patients without previous treat-
ment; hence, the therapeutic effect can be evaluated more
precisely and at an early stage due to the pathological exami-
nation that takes place at the time of surgery. This setting can
be described as an in vivo chemosensitivity test. In vitro stud-
ies have identified a large number of determinants that are
involved in mechanisms of resistance or sensitivity to chemo-
therapy [4]. The impact of these parameters has not been
established for routine use for the effect of chemotherapy in
humans. Preoperative treatment of breast cancer is ideal for
the evaluation of the predictive value of these molecular mark-
ers, as tumour tissue can be obtained before and after treat-
ment [5].
The oestrogen and progesterone receptor content of breast
carcinomas have been regarded as the only established
molecular markers capable of predicting the response to
endocrine treatment in large-scale trials [6,7]. In preoperative
trials, negative estrogens receptor status is strongly correlated
to an increased sensitivity of a preoperative chemotherapy [8].
The mechanisms underlying these effects are not fully under-
stood but in vitro studies have shown that ER signalling can
increase levels of bcl-2 and induce anthracycline resistance
[9].
Ki-67 is a nuclear antigen expressed in G1, S and G2 phase
but not in G0 or the resting phase of the cell cycle [10]. It has
become established as a proliferation marker in breast cancer.
A high level of proliferation activity has been found to have pre-
dictive value for the response to preoperative chemotherapy
[8]. Changes in the relative proportion of Ki-67 positive cells
have been observed early after preoperative chemotherapy. A
significant decrease 14 days after the initiation of neo-adjuvant
treatment with tamoxifen correlated with a better chance of
tumour response [11,12].
The prognostic and predictive value of human epidermal
growth factor receptor 2 (HER2) has been investigated in a
large number of publications [13] and was considered as a
marker of resistance for example, for the cyclophosphamide,
methotrexate, 5-fluorouracil (CMF) regimen or tamoxifen. Only
recently, overexpression of HER2 was correlated with a higher
sensitivity to taxanes [14].
Non-functional mutated p53 accumulates in the nucleus of
tumour cells, where it can be detected by immunohistochem-
istry. However, the antigenic site of the protein is truncated in
40% of the cases and cannot be detected by the antibody
used for immunohistochemistry. Undifferentiated tumours that
are negative for p53 have a high possibility for an allelic loss or
nonsense mutations. However, findings regarding the predic-
tive value of p53 mutations in breast cancer have been contra-
dictory. A large adjuvant trial of 595 patients showed that p53
mutations were predictive for a better effect of a higher dose
of doxorubicin [15], but this was not confirmed in a preopera-
tive trial of 329 patients [16].
The oncogene Bcl-2 is classically associated with follicular
lymphomas and appears to be associated with chemoresist-
ance in these types of tumours [17]. It is a cytosolic expressed
protein that interacts with p53 and other proteins and act as
inhibitor of apoptosis. Bcl-2 overexpression is described in
approximately 80% of primary breast cancer [18] but a clear
association with a chemoresistance has not been shown to
date. Therefore, the situation in breast cancer is less clear-cut
and needs further investigation [19].
Based on the promising results of a pilot phase IIa trial investi-
gating a preoperative dose-dense combination regimen of
doxorubicin and docetaxel (dose-dense Adriblastin and Taxo-
tere, ddAT) in primary breast tumours ≥ 3 cm in diameter [20],
the German Preoperative Adriamycin-Docetaxel (GEPARDO)
group has initiated a prospective, randomised, controlled
multi-centre trial for further evaluation of the safety of this
dose-dense schedule, with or without simultaneous adminis-
tration of tamoxifen [21]. The aim of the trial was to increase
the pCR rate by simultaneously adding tamoxifen to the chem-
otherapy. The results in relation to compliance, toxicity, and
efficacy have been reported previously.
The initially defined aim of the study was to assess various
biomarkers: oestrogen receptor (ER) and progesterone recep-
tor (PgR) content, Ki-67, HER2, p53 and bcl-2 in tissue
obtained from core-cut biopsies before start of treatment, and
to assess the value of these for predicting a pathological com-
plete response in comparison with various clinical and patho-
logical parameters.
Methods
Patient population
All patients had to meet the following major inclusion criteria
to be enrolled in the clinical trial: unilateral primary carcinoma
of the breast, confirmed histologically by core-cut needle or
incisional biopsy (fine-needle aspiration was not considered
sufficient); a tumour measurable two-dimensionally by mam-
mography, breast ultrasound or breast MRI; a primary tumourPage 2 of 11
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ticentric breast cancer, the largest lesion was measured); no
evidence of distant metastases (as confirmed by chest radiog-
raphy, liver ultrasound and bone scintigraphy); patient age
between 18 and 70 years; and provision by the patient of writ-
ten informed consent to participation in the study and to cen-
tral immunohistochemical examination of the tumour tissue.
Patients were excluded from participation if there was evi-
dence of locally advanced (stage IIIB), bilateral, metastatic, or
inflammatory breast cancer and if there had been previous
treatment for breast cancer including surgery, radiotherapy or
cytotoxic or endocrine treatments (surgical diagnostic proce-
dures were allowed). Participating centres had to confirm that
the trial was conducted according to the protocol recommen-
dations, and had to apply for approval from an ethics commit-
tee. The study was conducted in accordance with the Helsinki
Declaration. Complete source-data verification was provided
by bi-monthly visits from an external clinical research organisa-
tion. The entry of data into the central database was double-
checked and cross-checked by the responsible data-verifiers
and data-managers.
Study treatment and assessments
All patients received doxorubicin at a dosage of 50 mg/m2 and
docetaxel at a dosage of 75 mg/m2 every 14 days for four
cycles (ddAT). If they were randomly assigned to receive
chemoendocrine treatment, patients received tamoxifen as a
30-mg tablet once daily in the morning, beginning on day 1 of
the first cycle. All patients received lenograstim or filgrastim
subcutaneously on days 5 to 10. After completion of chemo-
therapy and assessment of the response, all patients under-
went surgery. Surgery had be performed 14 to 28 days after
the last chemotherapy cycle, which was 8 to 10 weeks after
the initiation of systemic therapy.
The size of the breast lump and axillary nodal status was deter-
mined by palpation before each cycle and before surgery. The
product of the two largest perpendicular diameters was used
to approximate the tumour area. In patients with multifocal or
multicentric breast cancer, the lesion with the largest diameter
was chosen for follow-up.
Clinical response after two cycles was defined according to
the following criteria: complete response (CR) when no breast
tumour was palpable; partial response (PR) when the reduc-
tion in the tumour area was ≥ 50%; and no change (NC) when
the tumour area was reduced < 50% or increased < 25%.
Progressive disease (PD) was recorded if the tumour area
increased ≥ 25%, or if a new lesion was detected. In the sur-
gical specimen, the classification of histological response pro-
posed by Sinn et al. [22] was used (grade 0: no effect; grade
I: resorption and tumour sclerosis; grade II: minimal focal inva-
sive residues of ≤ 5 mm; grade III: only non-invasive tumour
residues; grade IV: no viable tumour cell detectable). Only
grade IV regression was considered to represent as a patho-
logical complete response.
Histopathological and immunohistological studies
The core-cut specimens from the study patients were fixed in
4% (w/v) phosphate buffered formalin and embedded in par-
affin at the participating site, and then collected centrally for
further examination. A haematoxylin/eosin-stained section of
each block was prepared for central confirmation of the histo-
logical diagnosis and determination of the histological type
and grade [23]. Serial sections of 2 to 3 μm were mounted on
capillary-gap slides (DAKO Diagnostica, Hamburg, Germany)
and dried at 37°C. Immunohistochemical staining was per-
formed within 1 week. Slides were incubated at 60°C for 60
min and deparaffinised (2 × 5 min xylene followed by 5 min
each ethanol 95%, 90%, 70% and 2 × 1 min distilled water),
and treated with antigen retrieval buffer (DAKO) in a micro-
wave oven to unmask the antigens. Automated capillary-gap
technology staining with DAKO Techmate was carried out to
provide identical staining conditions. The following antibodies
(Ab) were used: ER: 1D5 (DAKO), dilution 1:100; PgR: poly-
clonal Ab (DAKO), dilution 1:100; Ki-67: MIB1 (Dianova,
Hamburg, Germany) dilution 1:200; HER2: polyclonal Ab
A0435 (DAKO), dilution 1:2,000; p53: mouse monoclonal
antibody DO7 (DAKO), dilution 1:100, bcl-2: 124 (DAKO),
dilution 1:100. Tissue sections were incubated with the pri-
mary antibodies for 25 min. As secondary antibodies, we used
a DAKO kit for 25 min. Endogenous peroxidase was blocked
with kit supplied H2O2. AEC (DAKO) was used as a chro-
mogen substrate, and slides were slightly counterstained with
haematoxylin.
Immunostaining was semiquantitatively graded according to
the proportion of positive cells. Tumours were considered ER-
positive or PgR-positive when 10 to 100% of all tumour cells
had nuclear staining for oestrogen receptor or progesterone
receptor, respectively. Tumours were categorised into three
groups in relation to the proliferative activity: low (0 to 15% of
tumour cells with nuclear staining for Ki-67), medium (16 to
30%), and high (31 to 100%). Normal p53 expression was
recorded when 1 to 50% of the tumour cells were positively
stained. Abnormal expression was detected when no tumour
cells, or 51 to 100% of the tumour cells, were positively
stained. HER2 staining was scored on a scale of 0 to 3+ using
the scoring system outlined in the DAKO Hercept Test. Only
unambiguous membrane staining was evaluated. Only HER2
3+ tumours were regarded as positive for overexpression. bcl-
2 was scored semiquantitatively (0+ to 3+) judging the cyto-
plasmatic expression of bcl-2, but tumours with 2+ and 3+
staining were regarded as having normal expression. All histo-
logical evaluations were carried out by two independent inves-
tigators (HPS, GvM).Page 3 of 11
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The probability of a pCR was estimated using (1) a univariate
logistic regression model for the following clinical factors
recorded at randomisation: menopausal status, tumour size,
nodal status, grade, and clinical response after two cycles of
ddAT; and (2) by immunohistochemistry findings: oestrogen
and progesterone hormone receptor status, Ki-67, HER2,
p53, and bcl-2. In a multivariate logistic regression analysis,
immunohistochemical markers alone, and clinical and biologi-
cal markers together and separated by treatment group, were
evaluated. Here, oestrogen and progesterone receptor status
were combined to make the 'hormonal receptor' factor, which
is positive when at least one of the underlying factors is posi-
tive. All factors were included in a backward logistic regres-
sion model. Patients with missing values were excluded from
the corresponding analysis. p Values greater than 0.05 were
reported as not significant (NS). In addition, a multivariate
logistic regression model for clinical response after two cycles
was established in order to assess the predictive value of
baseline factors on this intermediate measure.
Results
A total of 250 patients were recruited into the trial between
April 1998 and June 1999 by 56 participating centres all over
Germany. A total of 973 of 996 (97.7%) planned cycles of
ddAT were administered. The overall pCR rate for all patients
was 9.7%, as previously reported [21]. Sufficient tumour tis-
sue and information about pCR was detectable in 196 tumour
samples. The availability of core-cut biopsies and the detec-
tion of biomarkers are listed in Table 1.
Patients were premenopausal in 54.1% of the 196 analysed
cases. The tumours had a palpable diameter of more than 4
cm in 82 patients (41.8%). In all, 98 patients (50.0%) did not
have palpable enlarged axillary lymph nodes. The histological
differentiation was centrally determined as grade 1 in six
tumours (3.1%), as grade 2 in 84 tumours (43.3%) and as
grade 3 in 104 tumours (53.6%). A total of 96 patients
(51.9%) had a clinical complete or partial response after two
cycles of ddAT. ER-positive and PgR-positive tumours were
found in 56.1% and 39.3%, respectively. In all, 46 tumours
(23.7%) showed a HER2 overexpression with a score of 3+.
Proliferation activity of the tumours was low in 38.3% and high
in 39.8%. p53 and bcl-2 were normally expressed in 91
(46.4%) and 72 (36.7%) patients, respectively. All character-
istics were found to be well balanced in the two treatment
arms (Table 2).
The pCR rates in the various subgroups in relation to the vari-
ous clinical and biological factors are shown in Table 3. A pCR
rate below 4% was found in patients with ER-positive or PgR-
positive tumours, normal bcl-2 status, low and medium prolif-
eration activity, grade I/II differentiation, no clinical response
after two cycles of chemotherapy, or positive clinical nodal
status. A probability of a pCR of more than 15% was found in
patients with ER-negative tumours or high proliferation activity.
The clearest differences between the pCR rates for the two
treatment groups were seen in relation to Ki-67 and HER2.
Patients with a low Ki-67 percentage showed a better
response when treated with tamoxifen, whereas patients with
a high Ki-67 percentage did not benefit from tamoxifen treat-
ment. HER2-overexpressing tumours showed a similar
response to that in HER2-negative patients who were treated
without tamoxifen, but when patients with HER2-positive
tumours were treated with ddAT plus tamoxifen, no pCR was
detected. Highly differentiated ER-positive or PgR-positive
tumours were never completely eradicated with chemoendo-
crine treatment (Table 2).
In univariate logistic regression models, negative lymph nodes,
poor tumour differentiation, negative ER, negative PgR and
loss of bcl-2 were found to be significantly predictive of a pCR.
The highest odds ratios were found for ER, PgR and bcl-2,
with a more than 10 times higher chance of a pCR when the
expression changed from favourable to unfavourable (Table 3).
When only the experimental biological factors were included
in a multivariate logistic regression model, bcl-2 was found to
be a significant predictor of the efficacy of systemic therapy.
Patients with low bcl-2-expressing tumours achieved a pCR
9.4 (1.17 to 75.18) times more often than those who had
tumours with normal bcl-2 levels (Table 4).
For more complex models, oestrogen and progesterone
receptor status were combined to form the factor 'hormonal
receptor', which was defined to be positive if at least one of the
receptors, oestrogen or progesterone, is positive. If both
receptors are negative, hormonal receptor status is also nega-
tive. When all factors, established and experimental, were
included in the multivariate logistic regression model, clinical
nodal status and hormonal receptor were found to be signifi-
cant predictors of pCR. When clinical response after two
cycles was excluded from the analysis, the same factors were
still significant predictors (Table 5). Using the backward step-
wise elimination procedure (significance level 10%), a clinical
response after two cycles, lymph-node status, and hormonal
receptor were found to be significant predictors of a pCR. If a
clinical complete or partial response occurred after two
cycles, patients had a 3.3 times higher chance of achieving a
pCR at surgery than patients without a response. Patients with
hormonal receptor negative tumours had a 24.3 times higher
probability of achieving a pCR than patients with PgR-positive
tumours. A patient with clinically uninvolved axillary lymph
nodes had a 5.0 times higher chance of a pCR than a patient
with suspicious lymph nodes.
In addition, a multivariate regression model was performed to
predict the intermediate variable clinical response after twoPage 4 of 11
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2 proved to have a statistically significant impact on the clinical
response after two cycles (Table 6).
The distribution of pCR rates across subgroups of patients is
depicted in Table 7. It demonstrates that there is no significant
change in the pCR rates in the treatment arms within these
subgroups.
Discussion
Separating patients into groups depending on their predicted
tumour responses may offer a significant clinical advantage in
their management. The response to preoperative chemother-
apy correlates significantly with disease-free and overall sur-
vival. The occurrence of a clinical complete response
subsequent to the administration of neo-adjuvant chemother-
apy may be associated with only partial eradication of occult
metastatic disease. A pathological complete response is
therefore considered to be the optimal criterion, as it corre-
lates with a 5-year disease-free survival of 84% in stage I-IIIA
disease, whereas a clinical complete response leads to a 5-
year disease-free survival of only 76% [1,3,24,25]. Pathologi-
cal complete response has approximately the same prognostic
power as pathological lymph-node status [3], but whereas
lymph-node status is an existing condition that can only be
changed by early detection, the pCR rate can be improved by
using better systemic treatments. The fact that long-term dis-
ease-free survival is not achieved in all patients suggests that
Table 1
Progress of tumour biopsies throughout the study
Patients (n)
Patients randomised 250
To ddAT + tamoxifen 122
To ddAT – tamoxifen 128
Data on pCR available 247
No breast cancer 1
Chemotherapy refused 1
Surgery refused 1
Core biopsies available and evaluable 196
Not available 35
No tissue on block 6
Non-characteristic tissue 2
No tumour tissue on block 8
Results available for multivariate analysis (without clinical response after 2 cycles) 193
Multivariate analysis data missing for:
Menopausal stage 0
Tumour size 0
Nodal status 0
Grade 2
ER 0
PgR 0
Ki-67 0
HER2 2
p53 0
bcl-2 0
Results available for multivariate analysis (with clinical response after 2 cycles) 181
Multivariate analysis data missing for clinical response after two cycles 12
ddAT, dose-dense Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; 
pCR, pathological complete remission; PgR, progesterone receptor.Page 5 of 11
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Distribution of predictive factors in relation to subgroups and in relation to treatment, with corresponding rates for pCR
ddAT – Tamoxifen (n = 98) ddAT + Tamoxifen (n = 98)
n % pCR (%) n % pCR (%)
Menopausal status:
Premenopausal 50 51.0 10.0 56 57.1 12.5
Peri-/postmenopausal 48 49.0 8.3 42 42.9 2.4
Tumour size:
≤ 4 cm 58 59.2 12.1 56 57.1 8.9
> 4 cm 40 40.8 5.0 42 42.9 7.1
Clinical nodal status:
Negative 52 53.1 15.4 46 46.9 13.0
Positive 46 46.9 2.2 52 53.1 3.9
Grade:
I/II 46 47.9 4.3 44 44.9 0
III 50 52.1 14.0 54 55.1 14.8
Clinical response after two cycles:
cPR/cCR 45 48.9 13.3 50 54.3 12.0
cNC/cPD 47 51.1 4.3 42 45.7 4.8
ER:
0 to 9% 40 40.8 17.5 46 46.9 17.4
10 to 100% 58 59.2 3.5 52 53.1 0
PgR:
0 to 9% 55 56.1 14.5 64 65.3 12.5
10 to 100% 43 43.9 2.3 34 34.7 0
Ki-67:
0 to 15% 42 42.9 2.4 33 33.7 6.1
16 to 30% 21 21.4 0 22 22.5 4.5
31 to 100% 35 35.7 22.9 43 43.9 11.6
HER2:
0 to 2+ 73 76.0 9.6 75 76.5 10.7
3+ 23 24.0 8.7 23 23.5 0
p53:
1 to 50% 47 48.0 6.4 44 44.9 4.5
0 + 51 to 100% 51 52.0 11.8 54 55.1 11.1
bcl-2:
0 to 1+ 60 61.2 13.3 64 65.3 12.5
2 to 3+ 38 38.8 2.6 34 34.7 0
cCR, clinical complete response; cNC, clinical no change; cPD, clinical progressive disease; cPR, clinical partial response; ddAT, dose-dense 
Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological 
complete remission; PgR, progesterone receptor.Page 6 of 11
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the primary tumour. This has indeed been observed for lymph-
node metastases, which are less responsive to preoperative
systemic treatment than the primary tumour; the cause can
probably be attributed to distant 'micrometastases'.
Table 3
Univariate logistic regression for the predicting of a pCR irrespective of study treatment
pCR Odds ratio 95% CI
n %
Menopausal status:
Premenopausal 12 11.3 2.17 0.73 to 6.41
Peri-/postmenopausal 5 5.6
Clinical tumour size:
≤ 4 cm 12 10.5 1.81 0.61 to 5.36
> 4 cm 5 6.1
Clinical nodal status:
Negative 14 14.3 5.28 1.47 to 19.00
Positive 3 3.1
Grading:
Grade I + II 2 2.2 0.13 0.03 to 0.61
Grade III 15 14.4
Clinical response after: 2 cycles ddAT
cCR/cPR 12 12.6 3.07 0.95 to 9.91
cNC/cPD 4 4.5
ER:
0 to 9% 15 17.4 11.41 2.53 to 51.41
10 to 100% 2 1.8
PgR:
0 to 9% 16 13.5 11.81 1.53 to 90.97
10 to 100% 1 1.3
Ki-67:
0 to 15% 3 4.0 0.32 0.09 to 1.15
16 to 100% 14 11.6
HER2:
0 to 2+ 15 10.1 2.48 0.55 to 11.28
3+ 2 4.3
p53:
1 to 50% 5 5.5 0.45 0.15 to 1.33
0 + 51 to 100% 12 11.4
bcl-2:
0 to 1+ 16 12.9 10.52 1.36 to 81.09
2 to 3+ 1 1.4
cCR, clinical complete response; cNC, clinical no change; cPD, clinical progressive disease; cPR, clinical partial response; ER, oestrogen 
receptor; HER2 human epidermal growth factor receptor 2; pCR, pathological complete remission; PgR, progesterone receptor.Page 7 of 11
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within weeks after the start of treatment, and is therefore an
ideal way of comparing new active drugs. If achieving a pCR
could be predicted even earlier, breast cancer patients could
be saved from having to undergo ineffective treatment regi-
mens that do not translate into a tumour response in the pre-
operative setting.
A variety of proven and putative predictive markers (for exam-
ple, ER, PgR, ploidy, S-phase, HER2, p53, and other onco-
genes and growth factors) have been evaluated in previous
studies [19] in material obtained from fine-needle biopsies and
core-cut biopsies, and have been correlated with the tumour
response in order to assess whether unnecessary surgical or
radiological treatment can be avoided after systemic therapy,
or even whether systemic treatment can be avoided entirely. In
addition, there have been studies in which serial biopsies were
taken to examine changes in biological markers during therapy
and correlate these changes with the treatment outcome.
However, the populations examined were mostly below the
critical number of 100 patients, and only preliminary and con-
tradictory data were obtained.
As shown in Table 6, the predictive values of the factors stud-
ied are in fact strongly influenced by the type of treatment
given. The combination of tamoxifen with chemotherapy is det-
rimental to the investigation of predictive markers, since more
aggressive tumours react differently to chemotherapy, at least
during the short term of an 8-week treatment of the type used
in the present study, as proliferation is blocked by tamoxifen.
Admittedly, 196 patients are not sufficient to analyse a large
number of predictive factors simultaneously, so only large dif-
ferences can be distinguished. Another aspect that may be
criticised is that immunohistochemistry is not the best method
of detecting HER2 overexpression or p53 mutation, and this
may be the reason why more significant results were not
achieved. Moreover, the detection of a clinical response by
palpation after the second cycle is observer-dependent, and
might be replaced by more valid measurement methods such
as breast ultrasonography or magnetic resonance imaging.
However, all of these methods are currently widely used in
clinical routine.
The response after two cycles is influenced by a wide variety
of biological features representing the resistance or sensitivity
of the tumour to a specific treatment. This is evident from Table
5, where it can be seen the impact of most factors disap-
peared when this response factor was added to the multivari-
ate analysis. Since the response to chemotherapy has always
been regarded as multifactorial, this factor seems more appro-
priate than using a single factor for predicting pCR.
Table 4
Biomarkers in relation to their predictive value for achieving a 
pathological complete response: multivariate logistic 
regression in 194 patients
Odds ratio 95% CI p Value
Ki-67 0.43 0.11 to 1.61 0.208
HER2 4.05 0.87 to 18.95 0.076
p53 0.69 0.22 to 2.16 0.527
bcl-2 9.39 1.17 to 75.18 0.035
HER2, human epidermal growth factor receptor 2.
Table 5
Multivariate logistic regression analysis of established and experimental factors for predicting a pathological complete response, 
irrespective of study treatment: clinical response after two cycles excluded from second analysis
First analysis Second analysis
Odds ratio 95% CI p Value Odds ratio 95% CI p Value
Menopausal status 1.63 0.44 to 6.05 0.467 1.89 0.55 to 6.51 0.312
Tumour size 1.75 0.46 to 6.68 0.411 1.80 0.51 to 6.40 0.363
Clinical nodal status 5.48 1.24 to 24.16 0.025 5.44 1.35 to 21.87 0.017
Grade 0.21 0.03 to 1.33 0.098 0.16 0.03 to 0.91 0.039
Clinical response after two cycles 3.68 0.90 to 15.03 0.069 - - -
Hormonal receptor 27.00 2.21 to 330.57 0.010 7.83 1.24 to 49.42 0.029
Ki-67 0.75 0.16 to 3.56 0.716 0.78 0.18 to 3.39 0.740
HER2 4.09 0.70 to 24.08 0.119 3.66 0.69 to 19.30 0.126
p53 4.11 0.73 to 23.01 0.108 2.55 0.56 to 11.66 0.227
bcl-2 3.75 0.35 to 39.54 0.272 4.98 0.53 to 46.95 0.161
HER2, human epidermal growth factor receptor 2.Page 8 of 11
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confirmed that the response after two cycles, together with
tumour size and age, was a significant predictor of pCR [26].
In fact, in this study the response after two cycles was the only
independent predictor in the multivariate analysis.
Recently, a French group has demonstrated that patients, who
did not show a clinical response after three cycles of
preoperative chemotherapy with vinblastine, thiotepa, meth-
otrexate, and fluorouracil, achieved a secondary clinical
response in 40% of cases with a salvage regimen including
cisplatin, etoposide, fluorouracil, and mitomycin. Patients with
a clinical response to the first regimen had a 5-year overall sur-
vival rate of 82%, compared with 67% in those who did not
respond. However, in patients who responded to the second
regimen, the prognosis improved up to 82%, comparable to
that of initial responders, whereas patients with no response
at all showed a poor outcome with a 57% survival rate [27]. In
another pilot trial, 133 patients with large (> 3 cm) or locally
advanced tumours and a clinical response to four cycles of
cyclophosphamide, vincristine, doxorubicin and prednisolone
(CVAP) were randomly assigned either to continue for a fur-
ther four cycles with CVAP or to four cycles of docetaxel. The
pathological complete response rate in patients with eight
cycles of CVAP was 16%, compared with 34% in those with
CVAP and docetaxel. The response rate of non-responders
after salvage treatment with docetaxel was only 2% [28].
Table 6
Multivariate logistic regression analysis of established and experimental factors for predicting a clinical response after two cycles, 
irrespective of study treatment
Odds ratio 95% CI p Value
Menopausal status 1.35 0.72 to 2.55 0.351
Tumour size 0.93 0.49 to 1.75 0.821
Clinical nodal status 1.04 0.56 to 1.94 0.903
Grade 0.67 0.33 to 1.38 0.279
ER 1.09 0.43 to 2.77 0.850
PgR 0.56 0.23 to 1.35 0.195
Ki-67 0.58 0.29 to 1.15 0.120
HER2 0.99 0.46 to 2.16 0.990
p53 1.43 0.69 to 2.96 0.338
bcl-2 2.75 1.27 to 5.97 0.011
ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.
Table 7
Distribution of patients in subgroups by treatment with corresponding pCR rates
n (pCR)
ddAT – Tamoxifen (n = 98) ddAT + Tamoxifen (n = 98)
ER+ HER2+ 11 (1) 10 (0)
HER2- 46 (1) 42 (0)
HER2 status missing 1 (0) 0 (0)
Total 58 (2) 52 (0)
ER- HER2+ 12 (1) 13 (0)
HER2- 28 (6) 33 (8)
Total 40 (7) 46 (8)
Total 98 (9) 98 (8)
ddAT, dose-dense Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; 
pCR, pathological complete remission.Page 9 of 11
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Breast Cancer Research    Vol 10 No 2    von Minckwitz et al.Both of these trials demonstrate that the response to chemo-
therapy after a small number of cycles is not only predictive of
pCR and overall survival, but can also be influenced by non-
cross-resistant treatments. As demonstrated in the presented
study, the decision can already been taken after two cycles of
therapy, and patients can be spared from ineffective therapy at
a very early stage.
The validity of this observation still needs to be confirmed in a
large prospective randomised trial before the approach can be
introduced into routine clinical practice. Our group has there-
fore initiated a phase III trial in which non-responders to two
cycles of docetaxel, doxorubicin, and cyclophosphamide are
being randomly assigned to either continuation for a further
four cycles or to four cycles of a non-cross-resistant regimen
consisting of vinorelbine and capecitabine (Figure 1) [29].
Conclusion
Reliable prediction of a pathological complete response after
preoperative chemotherapy is not possible with clinical and
biological factors routinely determined before start of treat-
ment. The response after two cycles of chemotherapy is a
strong but dependent predictor. The only independent factor
in this subset of patients was bcl-2.
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